)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shanghai Junshi Biosciences Co
Shanghai Junshi Biosciences Co (1877) investor relations material
Shanghai Junshi Biosciences Co Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
9M 2026 operating income was RMB2,513m, up 39.18% YoY; net loss attributable to shareholders narrowed to RMB149.2m from RMB595.7m. Excluding share-based payment, net profit was RMB31.5m.
TUOYI domestic sales reached RMB1,964m, up 31% YoY; commercialized products drove revenue growth, and operating cash flow turned positive at RMB165.5m.
Financial highlights
Q3 revenue was RMB817.2m, up 28.19% YoY; Q3 total loss was RMB214.9m and net loss attributable to shareholders was RMB170.9m.
9M total loss narrowed to RMB248.3m from RMB692.4m; net loss attributable to shareholders narrowed to RMB149.2m from RMB595.7m.
9M operating cash flow was RMB165.5m versus an outflow of RMB343.4m; investing cash outflow was RMB1.728bn and financing cash inflow was RMB2.462bn.
9M net profit attributable to shareholders excluding share-based payment was RMB31.5m, an increase of RMB616.2m YoY.
Outlook and guidance
Priorities included improving R&D efficiency, strengthening commercial competitiveness, advancing global expansion and deepening operational management.
Development focus included biological products, selected-target research and combination regimens; clinical programs for JS207, JS212 and JS213 advanced.
Tifcemalimab plus toripalimab Phase III enrollment across 15 countries and 200+ centers was ongoing, with completion estimated in 2026; Phase III studies of JS107 in advanced gastric/GEJ cancer were underway, with a first-line combination study planned.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shanghai Junshi Biosciences Co
- Revenue up 17%, net loss narrowed 35%, and TUOYI® sales surged 50% with new approvals.1877
H1 2024 - Revenue up 53% in Q3 2024, with narrowed losses and strong drug sales driving growth.1877Q3 2024
- Revenue up 30%, net loss down 44%, driven by TUOYI® sales and global expansion.1877H2 2024
- Revenue up 31%, net loss narrows, and global expansion accelerates with new drug approvals.1877Q1 2025
- Revenue up 49% and net loss narrowed 36% on strong TUOYI® sales and global expansion.1877H1 2025
- Revenue up 42% and net loss narrowed, driven by strong drug sales and global expansion.1877Q3 2025
- Revenue up 28.23% YoY, net loss narrowed, driven by strong TUOYI® sales and global expansion.1877H2 2025
- Revenue up 45% and net loss narrowed, driven by robust drug sales and global expansion.1877Q1 2026
- Revenue up 45% YoY, profit turns positive, and global expansion accelerates.1877H1 2026
Next Shanghai Junshi Biosciences Co earnings date
H2 202612 Mar, 2027
Shanghai Junshi Biosciences Co
Next Shanghai Junshi Biosciences Co earnings date
H2 202612 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)